Zhejiang Langhua Pharmaceutical, a wholly owned subsidiary of Viva Biotech, (HKG:1873), passed the current good manufacturing practices (cGMP) onsite inspection conducted by the US Food and Drug Administration (FDA), according to a Thursday bourse filing.
The pharmaceutical company recently received the establishment inspection report from the US FDA, confirming the inspection's completion in line with the Code of Federal Regulations Title 21 (21 CFR).
The inspection, done in the second half of 2024, covered quality systems, materials, production, packaging and labeling systems, equipment and facilities, and laboratory control.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。